Agenus to Report Second Quarter 2015 Financial Results on July 23, 2015; Conference Call to Follow
July 16 2015 - 4:00PM
Business Wire
Agenus Inc. (NASDAQ: AGEN), an immunology company developing
innovative treatments for cancers and other diseases, will release
its second quarter 2015 financial results before the market opens
on Thursday, July 23, 2015. Agenus executives will host a
conference call at 11:00 a.m. Eastern Time the same day.
To access the live call, dial 1-866-233-4585 (U.S.) or
1-416-640-5946 (international). The call will also be webcast and
will be accessible from the company’s website at
www.agenusbio.com/webcast/. A replay will be available on the
company’s website approximately two hours after the call and will
remain available for 60 days. The replay number is 1-866-245-6755
(U.S.) 1-416-915-1035 (international), and the access code is
857826.
About Agenus
Agenus is an immunology company developing novel checkpoint
modulators, vaccines and adjuvants to treat cancer, infectious
diseases and other immune disorders. Using its proprietary
platforms Retrocyte DisplayTM and SECANT®, the Company is
discovering and developing novel antibodies to target GITR, OX40,
CTLA-4, LAG-3, TIM-3, PD-1 and other undisclosed checkpoints in
partnered and internal programs. Agenus’ heat shock protein
vaccine, Prophage, has successfully completed Phase 2 studies in
newly diagnosed glioblastoma multiforme. The Company’s QS-21
Stimulon® adjuvant is extensively partnered with GlaxoSmithKline
and Janssen Sciences Ireland UC, and two vaccine candidates
containing QS-21 have successfully completed Phase 3 trials. For
more information, please visit www.agenusbio.com, or follow the
company on Twitter @Agenus_Bio; information that may be important
to investors will be routinely posted in these locations.
Forward-Looking Statement
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding Agenus’ anticipated
timing for releasing its second quarter 2015 financial results.
These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include, among others, the factors
described under the Risk Factors section of Agenus’ Quarterly
Report on Form 10-Q filed with the Securities and Exchange
Commission for the period ended March 31, 2015. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150716006360/en/
Media:BMC CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.comorInvestors:Argot
PartnersAndrea Rabney, 212-600-1902andrea@argotpartners.comorJamie
Maarten, 212-600-1902jamie@argotpartners.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024